CAS: 53808-87-0; 5-(3,5-Dimethoxy-4-(2-Methoxyethoxy)Benzyl)Pyrimidine-2,4-Diamine

结构式图片

MSDS等安全信息

上下游产品

2,4-Diamino-5-(3,5-Dimethoxy-4-Hydroxybenzyl)Pyrimidine 21253-58-7

合成工艺路线路线简述

    📜胍 反应生成 四氧普林
    参考文献:Beck,Ivan;Egil,Janos;Jakfalvi,Elemer;Futdyga,Eva;Simonyi,Istvan;Lax,+
    标题:Beck,Ivan;Egil,Janos;Jakfalvi,Elemer;Futdyga,Eva;Simonyi,Istvan;Lax,+

    海关参考信息

    专利信息


    专利号:US-9693999-B2
    优先权日:2011-01-26
    标题:Small molecule RNase inhibitors and methods of use
    发明人:DUNMAN PAUL M; OLSON PATRICK D; CHILDERS WAYNE
    权利人:UNIV ROCHESTER; UNIV NEBRASKA; Temple University—Of the Commonwealth System of Higher Education
    摘要:Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.

    专利号:WO-2009056955-A1
    优先权日:2007-10-30
    标题 :Amine-bearing phospholipids (abps), their synthesis and use
    发明人:ZUMBUEHL ANDREAS
    权利人:UNIV BASEL; ZUMBUEHL ANDREAS
    摘要:Disclosed herein are amine-bearing phospholipids (ABP). The ABPs display many properties and functionalities of naturally occurring phospholipids, but also new properties and functionalities, such as the ability to polymerize while maintaining structural integrity, that may supplement or expand the functionalities of naturally occurring phospholipids.

    专利号:US-9868747-B2
    优先权日:2014-02-18
    标题:Marinopyrrole derivatives and methods of making and using same
    发明人:LI RONGSHI; SEBTI SAID; LIU YAN; QIN YONG; SONG HAO; CHENG CHUNWEI
    权利人:H LEE MOFFITT CANCER CT & RES; CHONGQING ZEIN PHARMACEUTICAL CO LTD
    摘要:Marinopyrrole derivatives and methods for their synthesis and use are described herein. Novel cyclic and symmetric marinopyrroles with triazole substituents having antibacterial activity against resistant bacterial strains, such as MRSA are introduced. Also provided are methods of using the compounds for treating or preventing cancer and/or microbial infections.

    专利号:US-9907753-B2
    优先权日:2010-03-19
    标 题 :Lipid vesicle compositions and methods of use
    发明人:IRVINE DARRELL J; MOON JAEHYUN
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.

    专利号:US-9295731-B2
    优先权日:2013-04-01
    标题 :Cleavable drug conjugates, compositions thereof and methods of use
    发明人:NGUYEN MARK QUANG
    权利人:NGUYEN MARK QUANG
    摘要:Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.

    专利号:US-2023398101-A1
    优先权日:2022-06-09
    标题 :Co-agents as Therapy Against Anaerobic Pathogens
    发明人:PACE JOHN LEE; HARTSELL THERESA LYNN
    权利人:FLEURIR ABX LLC
    摘要:Co-agent combinations and/or formulations herein unexpectedly display significantly better antimicrobial activity (e.g., more efficacy and/or more potency) against anaerobic pathogens not previously considered targets. With three or more co-agents, selected from a group of a fosfomycin, a diaminopyridine, a sulfonamide, a beta lactam antibacterial, a bacterial beta-lactamase inhibitor, a bacterial fosfomycin-modifying enzyme, and a bacterial peptidoglycan synthesis inhibitor, the therapeutic potential of the three or more co-agents is expanded by targeting a broader spectrum of pathogens. Co-agents, by unexpected synergistic action in an anaerobic environment, are now active and efficacious against difficult to treat pathogenic anaerobes (including anaerobes that cannot utilize oxygen and/or reside in an anaerobic environment, some being inhibited by oxygen), as well as pathogens considered resistant or intolerant to at least one of the co-agents when used singly in an anaerobic environment. Some co-agent combinations and/or formulations contain one or more existing antibiotic agents being repurposed for utility against difficult to treat anaerobic pathogens.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Kaur D, Mathew S, Nair CGS, Begum A, Jainanarayan AK, Sharma M, Brahmachari SK. Structure based drug discovery for designing leads for the non-toxic metabolic targets in multi drug resistant Mycobacterium tuberculosis. J Transl Med. 2017 Dec 21;15(1):261. doi: 10.1186/s12967-017-1363-9.
    2: Caira MR, Bettinetti G, Sorrenti M, Catenacci L. Order-disorder enantiotropy, monotropy, and isostructurality in a tetroxoprim-sulfametrole
    1:1 molecular complex: Crystallographic and thermal studies. J Pharm Sci. 2003 Nov;92(11):2164-76. doi: 10.1002/jps.10435. 91(2):467-81. doi: 10.1002/jps.10034. 86(1):70-8. doi: 10.1159/000045715. 5(6):361-8. 37(7):1436-43. doi: 10.1128/aac.37.7.1436.

    合成参考文献


    摘要:Journal of Chemotherapy., 5(400), 1993 []
    摘要:Buchtela K, Liebenow W, Vergin H. [Synthesis of radioactively labelled tetroxoprim (author's transl)]. Arzneimittelforschung. 1980;30(2):307–9.
    摘要:Vergin H. [Tissue distribution of 14C-tetroxoprim in the rat (author's transl)]. Arzneimittelforschung. 1980;30(2):309–13.
    摘要:Vergin H, Reutter FW, Sieber R, Ferber H. [Renal elimination kinetics of tetroxoprim and sulfadiazine in patients with renal insufficiency]. Arzneimittelforschung. 1980;30(2):313–7.
    摘要:Vergin H, Bishop GB. [High-performance liquid chromatographic determination of tetroxoprim and sulfadiazine in biological samples (author's transl)]. Arzneimittelforschung. 1980;30(2):317–9.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知